Department of Cardio-thoracic Surgery, Catharina Hospital, Eindhoven, The Netherlands.
Eur J Cardiothorac Surg. 2009 Nov;36(5):856-62. doi: 10.1016/j.ejcts.2009.05.032. Epub 2009 Jul 17.
The optimal timing for discontinuation of clopidogrel before surgery remains under debate. The purpose of this study is to determine the effect of preoperative clopidogrel administration on postoperative blood loss and the total requirements of homologous blood products after coronary artery bypass grafting (CABG). We also evaluated the perioperative complications.
Consecutive patients (n=130) undergoing elective CABG were recruited and randomised between 2006 and 2007. In 38 patients (group 1), treatment with clopidogrel was discontinued 5 days prior to surgery, in 40 patients (group 2) 3 days before surgery and in 40 other patients (group 3) clopidogrel was stopped on the day of surgery.
Significantly more postoperative blood loss was observed in group 3 compared to group 1 (929+/-472 ml vs 664+/-312 ml; p=0.009). Other group comparisons were not significant. Blood loss after 12 h and at drain removal was also significantly higher in group 3. Patients in group 3 also had higher total requirements of homologous blood products (p=0.046) and a significantly higher need for fresh frozen plasma (FFP) transfusion (p=0.034). Univariable regression analyses revealed that continuing clopidogrel till the day of surgery (group 3) was predictive for postoperative blood loss (beta=0.289; p=0.007) and the total requirements of homologous blood products after surgery (beta=0.280; p=0.008). These effects remained the same in multivariable analyses.
Continuation of clopidogrel until the day of surgery induces significantly more postoperative blood loss and increases significantly the total requirements of homologous blood products and FFP transfusion after surgery. The blood loss and the use of blood products in the group that stopped at 3 days preoperatively were similar to that of the group that stopped at 5 days preoperatively.
关于术前停用氯吡格雷的最佳时机仍存在争议。本研究旨在确定冠状动脉旁路移植术(CABG)前应用氯吡格雷对术后失血和同源血液制品总需求的影响。我们还评估了围手术期并发症。
连续入选 2006 年至 2007 年接受择期 CABG 的患者,并进行随机分组。38 例患者(第 1 组)术前 5 天停用氯吡格雷,40 例患者(第 2 组)术前 3 天停用氯吡格雷,40 例患者(第 3 组)在手术当天停用氯吡格雷。
与第 1 组相比,第 3 组术后失血明显更多(929±472ml 比 664±312ml;p=0.009)。其他组间比较无显著差异。第 3 组术后 12 小时和引流管取出时的失血也明显更高。第 3 组患者对同源血液制品的总需求也更高(p=0.046),对新鲜冷冻血浆(FFP)的输血需求也更高(p=0.034)。单变量回归分析显示,直到手术当天继续使用氯吡格雷(第 3 组)与术后失血(β=0.289;p=0.007)和术后同源血液制品总需求(β=0.280;p=0.008)相关。多变量分析结果相同。
直到手术当天继续使用氯吡格雷会导致明显更多的术后失血,并显著增加术后同源血液制品和 FFP 的总需求。术前 3 天停药组和术前 5 天停药组的失血和血液制品使用情况相似。